Jefferies Financial Group Inc. Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Jefferies Financial Group Inc.

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$233.81 - $287.01 $10.8 Million - $13.2 Million	46,000 Added 920.0%	51,000 $14 Million
Q1 2024 May 13, 2024	SELL	$146.51 - $198.2 $1.32 Million - $1.78 Million	-9,000 Reduced 64.29%	5,000 $747,000
Q4 2023 Feb 13, 2024	SELL	$151.41 - $196.57 $1.11 Million - $1.43 Million	-7,300 Reduced 34.27%	14,000 $2.68 Million
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $1.42 Million - $1.76 Million	-8,300 Reduced 28.04%	21,300 $3.77 Million
Q2 2023 Aug 14, 2023	SELL	$185.01 - $212.05 $3.96 Million - $4.54 Million	-21,400 Reduced 41.96%	29,600 $5.62 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $4.53 Million - $5.84 Million	24,800 Added 94.66%	51,000 $10.2 Million
Q4 2022 Sep 21, 2023	SELL	$185.53 - $241.31 $630,802 - $820,454	-3,400 Reduced 11.49%	26,200 $6.23 Million
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $4.86 Million - $6.32 Million	26,200 New	26,200 $6.23 Million

642

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.6B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

Stay updated on Jefferies Financial Group Inc. with notifications on news.